The selective 5-HT(1A) receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets

l-DOPA is the gold-standard pharmacotherapy for treatment of Parkinson's disease (PD) but can lead to the appearance of troubling dyskinesia which are attributable to ‘false neurotransmitter’ release of dopamine by serotonergic neurons. Reducing the activity of these neurons diminishes l-DOPA-i...

Descripción completa

Detalles Bibliográficos
Autores principales: Fisher, Ria, Hikima, Atsuko, Morris, Rebecca, Jackson, Michael J., Rose, Sarah, Varney, Mark A., Depoortere, Ronan, Newman-Tancredi, Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pergamon Press 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103782/
https://www.ncbi.nlm.nih.gov/pubmed/32057799
http://dx.doi.org/10.1016/j.neuropharm.2020.107997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103782/
https://www.ncbi.nlm.nih.gov/pubmed/32057799
http://dx.doi.org/10.1016/j.neuropharm.2020.107997

Ejemplares similares